Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 15, 2023

Nab-Paclitaxel vs Solvent-Based Paclitaxel Followed by Epirubicin Plus Cyclophosphamide for High-Risk HR+/HER2− Early Breast Cancer

Annals of Oncology


Additional Info

Annals of Oncology
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
Ann. Oncol 2023 Apr 14;[EPub Ahead of Print], O Gluz, S Kuemmel, U Nitz, M Braun, K Lüdtke-Heckenkamp, R von Schumann, M Darsow, H Forstbauer, J Potenberg, C Uleer, EM Grischke, B Aktas, C Schumacher, C Zu Eulenburg, R Kates, K Jóźwiak, M Graeser, R Wuerstlein, R Baehner, M Christgen, HH Kreipe, N Harbeck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading